Legend Biotech Corporation
LEGN
Rang in aandelen
#4427
Legend Biotech Corporation, through its subsidiaries, operates as a... Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
Aandeelprijs
$19.04
Laatst gesynchroniseerd: 2026-10-20
Marktkapitalisatie
$3.52B
Verandering (1 dag)
2.09%
Verandering (1 jaar)
-42.06%
Land
US
Handel Legend Biotech Corporation (LEGN)
Categorie
Healthcare
P/B-ratio voor Legend Biotech Corporation (LEGN)
P/B-ratio op October 2026 TTM: 2.90
Volgens de meest recente financiële rapporten en aandelenkoers van Legend Biotech Corporation is de huidige P/B-ratio (TTM) 2.90. Eind 2023 had het bedrijf een P/B-ratio van 4.23.
P/B-ratiohistoriek voor Legend Biotech Corporation van 2017 tot 2026
P/B-ratio aan het einde van elk jaar
| Jaar | P/B-ratio | Wijzigen |
|---|---|---|
| 2026 (TTM) | 2.90 | 1.24% |
| 2024 | 2.86 | -32.46% |
| 2023 | 4.23 | -20.63% |
| 2022 | 5.33 | -23.44% |
| 2021 | 6.97 | 17.36% |
| 2020 | 5.94 | -129.87% |
| 2019 | -19.88 | -109.29% |
| 2018 | 213.90 | 6.56% |
| 2017 | 200.73 | 0.00% |
P/B-ratio voor vergelijkbare bedrijven of concurrenten
| Bedrijf | P/B-ratio | Verschil in P/B-ratio | Land |
|---|---|---|---|
| 6.251 | 115.89% |
US
|
|
| 13.2547 | 357.77% |
US
|
|
| 4.208 | 45.33% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | 113.52% |
NL
|
